Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate

Nuclear Medicine and Biology

Volumn 37, Issue 5, 2010, Pages 637-644

  Mairinger, Severin ^a,b,c   Langer, Oliver ^b,c   Kuntner, Claudia ^b   Wanek, Thomas ^b   Bankstahl, Jens P ^d   Bankstahl, Marion ^d   Stanek, Johann ^c   Dörner, Bernd ^a   Bauer, Florian ^a,c   Baumgartner, Christoph ^e   Löscher, Wolfgang ^d   Erker, Thomas ^a   Müller, Markus ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b AIT AUSTRIAN INSTITUTE OF TECHNOLOGY   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^e UNIVERSITY OF VIENNA   (Austria)

Author keywords

Blood brain barrier; Breast cancer resistance protein; Inhibitor; P glycoprotein; PET; Tariquidar

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; METHYL 4 ((4 (2 (6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL)ETHYL)PHENYL)AMINO CARBONYL) 2 (QUINOLINE 2 CARBONYLAMINO)BENZOATE C 11; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG; ABC TRANSPORTER; ABCG2 PROTEIN, MOUSE; BENZOIC ACID DERIVATIVE; METHYL 4-((4-(2-(6,7-DIMETHOXY-1,2,3,4-TETRAHYDROISOQUINOLIN-2-YL)ETHYL)PHENYL)AMINOCARBONYL)-2-(QUINOLINE-2-CARBONYLAMINO)BENZOATE; MULTIDRUG RESISTANCE PROTEIN; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN TISSUE; BREAST CANCER; IN VIVO STUDY; MOUSE; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RADIATION DOSE; SYNTHESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD BRAIN BARRIER; DIAGNOSTIC USE; DRUG SCREENING; DRUG STABILITY; FEMALE; GENE INACTIVATION; GENETICS; METABOLISM; SCINTISCANNING;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BENZOATES; BLOOD-BRAIN BARRIER; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; FEMALE; GENE KNOCKOUT TECHNIQUES; MICE; P-GLYCOPROTEIN; POSITRON-EMISSION TOMOGRAPHY; QUINOLINES; RADIOACTIVE TRACERS;

EID: 77953812375     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.02.008     Document Type: Article

References (26)

1. Vlaming M.L., Lagas J.S., Schinkel A.H. Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv Drug Deliv Rev 2009, 61(1):14-25.
2. Lagas J.S., Vlaming M.L., Schinkel A.H. Pharmacokinetic assessment of multiple ATP-binding cassette transporters: the power of combination knockout mice. Mol Interv 2009, 9(3):136-145.
3. Kamiie J., Ohtsuki S., Iwase R., Ohmine K., Katsukura Y., Yanai K., et al. Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res 2008, 25(6):1469-1483.
4. Dauchy S., Dutheil F., Weaver R.J., Chassoux F., Daumas-Duport C., Couraud P.O., et al. ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J Neurochem 2008, 107(6):1518-1528.
5. Matsson P., Pedersen J.M., Norinder U., Bergstrom C.A., Artursson P. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 2009, 26(8):1816-1831.
6. Kannan P., John C., Zoghbi S.S., Halldin C., Gottesman M.M., Innis R.B., et al. Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther 2009, 86(4):368-377.
7. 11C-verapamil and PET. J Nucl Med 2008, 49(8):1328-1335.
8. 11C-verapamil and PET. J Nucl Med 2009, 50(12):1954-1961.
9. 11C-N-desmethyl-loperamide in monkeys. J Nucl Med 2009, 50(1):108-115.
10. 11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nucl Med Biol 2009, 36(6):643-649.
11. 11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. J Med Chem 2009, 52(19):6073-6082.
12. 11C]tariquidar [symposium abstract]. Eur J Nucl Med Mol Imaging 2009, 36(Suppl 2):S222.
13. Rabindran S.K., Ross D.D., Doyle L.A., Yang W., Greenberger L.M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 2000, 60(1):47-50.
14. Allen J.D., van Loevezijn A., Lakhai J.M., van der Valk M., van Tellingen O., Reid G., et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 2002, 1(6):417-425.
15. Fox E., Bates S.E. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther 2007, 7(4):447-459.
16. Robey R.W., Steadman K., Polgar O., Morisaki K., Blayney M., Mistry P., et al. Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 2004, 64(4):1242-1246.
17. Kühnle M., Egger M., Müller C., Mahringer A., Bernhardt G., Fricker G., et al. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. J Med Chem 2009, 52(4):1190-1197.
18. 11C]methane. Appl Radiat Isot 1997, 48(2):153-157.
19. 11C]methyl triflate. Appl Radiat Isot 1992, 43:1383-1385.
20. Loening A.M., Gambhir S.S. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2003, 2(3):131-137.
21. 11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. Nucl Med Biol 2005, 32(1):87-93.
22. 11C]tariquidar in transporter knockout mice [symposium abstract]. Nuklearmedizin 2009, 48(6):A143.
23. de Vries N.A., Zhao J., Kroon E., Buckle T., Beijnen J.H., van Tellingen O. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res 2007, 13(21):6440-6449.
24. Polli J.W., Olson K.L., Chism J.P., John-Williams L.S., Yeager R.L., Woodard S.M., et al. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos 2009, 37(2):439-442.
25. Mandema J.W., Gubbens-Stibbe J.M., Danhof M. Stability and pharmacokinetics of flumazenil in the rat. Psychopharmacology (Berl) 1991, 103(3):384-387.
26. Shao X., Lisi J.M., Butch E.R., Kilbourn M.R., Snyder S.E. N-methylpiperidinemethyl, N-methylpyrrolidyl and N-methylpyrrolidinemethyl esters as PET radiotracers for acetylcholinesterase activity. Nucl Med Biol 2003, 30(3):293-302.